|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2001-1-9
|
|
pubmed:abstractText |
HuM291 is a humanized anti-CD3 monoclonal antibody engineered to reduce binding to Fcgamma receptors and complement fixation. HuM291 has a long serum half-life and mediated profound depletion of circulating T cells in chimpanzees; HuM291 also has significantly less mitogenic and cytokine-releasing activity than OKT3 in vitro.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0041-1337
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
27
|
|
pubmed:volume |
70
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1707-12
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11152101-Adult,
pubmed-meshheading:11152101-Aged,
pubmed-meshheading:11152101-Animals,
pubmed-meshheading:11152101-Antibodies, Monoclonal,
pubmed-meshheading:11152101-Antigens, CD3,
pubmed-meshheading:11152101-Cytokines,
pubmed-meshheading:11152101-Dose-Response Relationship, Immunologic,
pubmed-meshheading:11152101-Female,
pubmed-meshheading:11152101-Graft Rejection,
pubmed-meshheading:11152101-Humans,
pubmed-meshheading:11152101-Kidney Failure, Chronic,
pubmed-meshheading:11152101-Kidney Transplantation,
pubmed-meshheading:11152101-Living Donors,
pubmed-meshheading:11152101-Lymphocyte Depletion,
pubmed-meshheading:11152101-Male,
pubmed-meshheading:11152101-Mice,
pubmed-meshheading:11152101-Middle Aged,
pubmed-meshheading:11152101-Pan troglodytes,
pubmed-meshheading:11152101-T-Lymphocytes
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors.
|
|
pubmed:affiliation |
Oregon Health Sciences University, Portland 97201, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase I
|
